MARKET

REXN

REXN

REXAHN PHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
-0.030
-1.23%
Closed 16:00 05/22 EDT
OPEN
2.551
PREV CLOSE
2.430
HIGH
2.551
LOW
2.275
VOLUME
18.92K
TURNOVER
--
52 WEEK HIGH
5.77
52 WEEK LOW
1.263
MARKET CAP
9.65M
P/E (TTM)
-1.4023
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REXN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

REXN News

More
Rexahn bails on cancer candidate RX-5902 in triple negative breast cancer
Seeking Alpha - Article · 04/09 10:53
Rexahn 8-K Shows Co. Notified Merck Sharp & Dohme On Apr. 7 Of Termination Of Clinical Trial Collaboration, Supply Deal Related To RX-5902 For Breast Cancer
Benzinga · 04/09 10:22
Does The Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) Share Price Tend To Follow The Market?
Simply Wall St. · 04/08 17:32
Rexahn Pharma Shares See Spike In Volume; Hearing Co. Granted US Patent '101 For 'Quinoxalinyl-piperazinamide methods of use'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10570101.PN.&OS=PN/10570101&RS=PN/10570101
Benzinga · 02/25 15:10
CYBR, BBBY among premarket losers
Seeking Alpha - Article · 02/12 14:17
Mid-Afternoon Market Update: Dow Rises 50 Points; Sprint Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.18% to 29327 while the NASDAQ rose 0.67% to 9,693.02. The S&P also rose, gaining 0.48% to 3,368.03.
Benzinga · 02/11 19:34
s, REXN, DBD and PYX among midday movers
Seeking Alpha - Article · 02/11 17:37
Mid-Day Market Update: Amkor Technology Surges On Upbeat Q4 Results; Phio Pharmaceuticals Shares Plummet
Midway through trading Tuesday, the Dow traded up 0.19% to 29,333.28 while the NASDAQ rose 0.8% to 9,705.16. The S&P also rose, gaining 0.54% to 3,370.08.
Benzinga · 02/11 17:08

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About REXN

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's pipeline features two clinical stage oncology product candidates and additional compounds in preclinical development. Its pipeline includes RX-3117, RX-5902 and RX-0301. RX-3117 is an investigational oral small molecule nucleoside compound. RX-5902 is a potential small molecule modulator of the Wnt/beta-catenin pathway, which plays a role in cancer cell proliferation and tumor growth. RX-5902 modulates the pathway through inhibition of phosphorylated p68, a protein that helps to transport beta-catenin from the cytoplasm into the cell nucleus. RX-0301 is being developed as a nano-liposomal formulation of RX-0201, an antisense oligonucleotide compound that is complementary to mRNA coding for Akt-1.
More

Webull offers kinds of Rexahn Pharmaceuticals, Inc. stock information, including NASDAQ:REXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REXN stock news, and many more online research tools to help you make informed decisions.